One study investigator pointed to the data for ADP-A2M4 as indicating much greater efficacy in the rare cancer than existing therapy options, while another said it demonstrated cell therapies’ potential outside of the blood cancer space.
[ad_2]
Source link
source https://earn8online.com/index.php/12183/adaptimmunes-asco-data-for-cell-therapy-in-sarcoma-spark-optimism-about-phase-ii-study-potential/
No comments:
Post a Comment